Skip to main content
M. Brooke Beavers Bernhardt, PharmD, MS, FCCP
Brooke Beavers Bernhardt, PharmD, MS, FCCP

Brooke Beavers Bernhardt, PharmD, MS, FCCP

Associate Member, St. Jude Faculty

  • Chief Pharmaceutical Officer
  • Vice-Chair for Pharmacy Services



  • MS (Pharmacy Administration) - University of Houston, Houston, Texas
  • PharmD – University of Georgia, Athens, Georgia
  • Residency (PGY1) – University of Alabama-Birmingham Hospital/Health System, Birmingham, Alabama
  • Residency (PGY2) – University of Virginia Health System, Charlottesville, Virginia

Honors & Awards 

  • 2022 - Fellow, American College of Clinical Pharmacy
  • 2010 - Houston/Galveston Region Outstanding Clinical Preceptor, University of Texas College of Pharmacy
  • 2009 - Pediatric House Staff Award of Appreciation, Baylor College of Medicine

Research Interests

  • Pharmacogenomics of treatment-related toxicity and outcomes in pediatric cancer
  • Novel drug development and therapeutic repurposing in pediatric oncology and hematology
  • Epidemiology and population sciences in pediatric oncology and hematology
  • Pharmacoeconomics and outcomes research

Selected Publications

Taylor ZL, Miller TP, Poweleit EA, DeGroote NP, Pommert L, Awoniyi O, Board SG, Ugboh N, Joshi V, Ambrosino N, Chavana A, Bernhardt MB, Schafer ES, O'Brien MM, Castellino SM, Ramsey LB. Clinical covariates that improve the description of high dose methotrexate pharmacokinetics in a diverse population to inform Clin Transl Sci Jul 28, 2023. doi: 10.1111/cts.13600. Epub ahead of print. PMID: 37503924

Ostrenga AR, Thackray J, McLearan HH, Mulieri KM, Bisaccia E, Militano O, Dupuis LL, Bernhardt MB; COG Pharmacy Discipline Steering Committee. Children's Oncology Group's 2023 blueprint for research: Pharmacy. Pediatr Blood Cancer Jul 17:e30581, 2023. doi: 10.1002/pbc.30581. Epub ahead of print. PMID: 37460409

Schoon S, Makamo N, Uittenboogaard A, Bernhardt MB, Ozuah NW, Kaspers GJL, Huibers MHW. Impact of undernutrition on the pharmacokinetics of chemotherapy in children with cancer: A systematic review. Pediatr Blood Cancer Jul 1:e30531, 2023. doi: 10.1002/pbc.30531. Epub ahead of print. PMID: 37393425

Hogan LE, Brown PA, Ji L, Xu X, Devidas M, Bhatla T, Borowitz MJ, Raetz EA, Carroll A, Heerema NA, Zugmaier G, Sharon E, Bernhardt MB, Terezakis SA, Gore L, Whitlock JA, Hunger SP, Loh ML. Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse. J Clin Oncol May 31;JCO2202200, 2023. doi: 10.1200/JCO.22.02200. Epub ahead of print. PMID: 37257143

Stevens AM, Schafer ES, Li M, Terrell M, Rashid R, Paek H, Bernhardt MB, Weisnicht A, Smith WT, Keogh NJ, Alozie MC, Oviedo HH, Gonzalez AK, Ilangovan T, Mangubat-Medina A, Wang H, Jo E, Rabik CA, Bocchini C, Hilsenbeck S, Ball ZT, Cooper TM, Redell MS. Repurposing atovaquone as a therapeutic against acute myeloid leukemia (AML): combination with conventional chemotherapy is feasible and well tolerated. Cancers (Basel) 15(4):1344, 2023. doi: 10.3390/cancers15041344. PMID: 36831684; PMCID: PMC9954468

Zobeck M, Bernhardt MB, Kamdar KY, Rabin KR, Lupo PJ, Scheurer ME. Novel and replicated clinical and genetic risk factors for toxicity from high-dose methotrexate in pediatric acute lymphoblastic leukemia. Pharmacotherapy Mar;43(3):205-214, 2023. doi: 10.1002/phar.2779. Epub ahead of print. PMID: 36764694

Unguru Y, Bernhardt MB, Berg SL, Marie-Johnson L, Grimm KP, Woodman C, Fernandez CV. Essential medicines for childhood cancer in Europe. Lancet Oncol Feb;24(2):e67, 2023. doi: 10.1016/S1470- 2045(23)00009-8. PMID: 36725147

Harris RD, Bernhardt MB, Zobeck MC, Taylor OA, Gramatges MM, Schafer ES, Lupo PJ, Rabin KR, Scheurer ME, Brown AL. Ethnic-specific predictors of neurotoxicity among patients with pediatric acute lymphoblastic leukemia after high-dose methotrexate. Cancer Apr 15;129(8):1287-1294, 2023. doi: 10.1002/cncr.34646. Epub ahead of print Jan 24, 2023. PMID: 36692972

Eckstein OS, Bernhardt MB, Hood CG, Karri V, Kralik SF, McClain KL. Treatment of Langerhans cell histiocytosis with subcutaneous cytarabine. Pediatr Hematol Oncol 10:1-9, 2023. doi: 10.1080/08880018.2022.2137609. Epub ahead of print. PMID: 36625721

Bernhardt MB, Brown AL, Grim AT, Scheurer ME, El-Mallawany NK, Ozuah NW. Safety analysis of high-dose methotrexate in pediatric non-Hodgkin lymphomas. Pediatr Blood Cancer 69(11):e29940, 2022. doi: 10.1002/pbc.29940. Epub 2022 Sep 7. PMID: 36069680

Dharia P, Swartz MD, Bernhardt MB, Chen H, Gramatges MM, Lupo PJ, Brown AL, Scheurer ME. Clinical and demographic factors contributing to asparaginase-associated toxicities in children with acute lymphoblastic leukemia. Leuk Lymphoma 63(12):2948-2954, 2022. doi: 10.1080/ 10428194.2022.2102621. Epub 2022 Jul 27. PMID: 35895075; PMCID: PMC9745725

Dong EE, Bruno MA, Kim JJ, Bernhardt MB, Brown AL, Gramatges MM. Distribution and frequency of tyrosine kinase inhibitor-associated long-term complications in children with chronic myeloid leukemia. Pediatr Blood Cancer 69(9):e29786, 2022. doi: 10.1002/pbc.29786. Epub 2022 May 20. PMID: 35593027

Russell HV, Chi YY, Okcu MF, Bernhardt MB, Rodriguez-Galindo C, Gupta AA, Hawkins DS. Rising drug cost impacts on cost-effectiveness of 2 chemotherapy regimens for intermediate-risk rhabdomyosarcoma: A report from the children's oncology group. Cancer 128(2):317-325, 2022. doi: 10.1002/cncr.33917. Epub 2021 Oct 8. PMID: 34623638; PMCID: PMC8738099

Schraw JM, Woodhouse JP, Bernhardt MB, Taylor OA, Horton TM, Scheurer ME, Okcu MF, Rabin KR, Lupo PJ, Brown AL. Comparison of the blood, bone marrow, and cerebrospinal fluid metabolomes in children with b-cell acute lymphoblastic leukemia. Sci Rep 11(1):19613, 2021. doi: 10.1038/s41598-021-99147-6. PMID: 34608220; PMCID: PMC8490393

Holle LM, Bilse T, Alabelewe RM, Kintzel PE, Kandemir EA, Tan CJ, Weru I, Chambers CR, Dobish R, Handel E, Tewthanom K, Saeteaw M, Dewi LKM, Schwartz R, Bernhardt B, Garg M, Chatterjee A, Manyau P, Chan A, Bayraktar-Ekincioglu A, Aras-Atik E, Harvey RD, Goldspiel BR. International Society of Oncology Pharmacy Practitioners (ISOPP) position statement: Role of the oncology pharmacy team in cancer care. J Oncol Pharm Pract 27(4):785-801, 2021. doi: 10.1177/10781552211017199. Epub 2021 May 22. PMID: 34024179

Zobeck MC, Bernhardt MB, Kamdar KY, Rabin KR, Lupo PJ, Scheurer ME. Novel risk factors for glucarpidase use in pediatric acute lymphoblastic leukemia: Hispanic ethnicity, age, and the ABCC4 gene. Pediatr Blood Cancer 68(8):e29036, 2021. doi: 10.1002/pbc.29036. Epub 2021 Mar 31

Brown PA, Ji L, Xu X, Devidas M, Hogan LE, Borowitz MJ, Raetz EA, Zugmaier G, Sharon E, Bernhardt MB, Terezakis SA, Gore L, Whitlock JA, Pulsipher MA, Hunger SP, Loh ML. Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: A randomized clinical trial. JAMA 325(9):833-842, 2021. doi: 10.1001/jama.2021.0669. PMID: 33651090; PMCID: PMC7926290

Kirk SE, Scheurer ME, Bernhardt MB, Mahoney DH, Powers JM. Phosphorus levels in children treated with intravenous ferric carboxymaltose. Am J Hematol Jun 1;96(6):E215-E218, 2021. doi: 10.1002/ajh.26165. Epub 2021 Apr 7. PMID: 33735470; PMCID: PMC8113159

McAtee CL, Lubega J, Underbrink K, Curry K, Msaouel P, Barrow M, Muscal E, Lotze T, Srivaths P, Forbes LR, Allen C, Bernhardt MB. Association of rituximab use with adverse events in children, adolescents, and young adults. JAMA Netw Open 4(2):e2036321, 2021. doi: 10.1001/jamanetworkopen.2020.36321. PMID: 33533931; PMCID: PMC7859842

Bernhardt MB, Lindsay H, Allen-Rhoades W, Foster JH. The Best Pharmaceuticals for Children Act and Pediatric Research Equity Act reach the age of majority-An oncology perspective. Pediatr Blood Cancer 68(3):e28871, 2021. doi: 10.1002/pbc.28871. Epub 2020 Dec 31. PMID: 33381908

Bernhardt MB, Militano O, Honeyford L, Zupanec S. Blinatumomab use in pediatric ALL: Taking a BiTE out of preparation, administration and toxicity challenges. J Oncol Pharm Pract 27(2):376-388, 2021. doi: 10.1177/1078155220979047. Epub 2020 Dec 18. PMID: 33334253

Brown AL, Raghubar KP, Taylor OA, Bernhardt MB, Kahalley LS, Pan W, Lupo PJ, Hockenberry MJ, Scheurer ME. Prospective patient-reported symptom profiles associated with pediatric acute lymphoblastic leukemia relapse. Support Care Cancer 29(5):2455-2464, 2021. doi: 10.1007/s00520-020-05773-7. Epub 2020 Sep 14. PMID: 32929538; PMCID: PMC8011637

Brown AL, Sok P, Taylor O, Woodhouse JP, Bernhardt MB, Raghubar KP, Kahalley LS, Lupo PJ, Hockenberry MJ, Scheurer ME. Cerebrospinal Fluid Metabolomic Profiles Associated With Fatigue During Treatment for Pediatric Acute Lymphoblastic Leukemia. J Pain Symptom Manage 61(3):464-473, 2021. doi: 10.1016/j.jpainsymman.2020.08.030. Epub 2020 Sep 1. PMID: 32889041; PMCID: PMC7914130

Whittle SB, Smith V, Silverstein A, Parmeter M, Minard CG, Bernhardt MB, Zage PE, Venkatramani R, Nuchtern JG, Heczey A, Russell HV, Shohet JM, Foster JH. Is high-risk neuroblastoma induction chemotherapy possible without G-CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors. Pediatr Blood Cancer 67(10):e28417, 2020. doi: 10.1002/pbc.28417. Epub 2020 Jul 30. PMID: 32729196; PMCID: PMC7722106

Last update: September 2023